Then don’t miss Issue 33 of The Altascientist where we explore how a comprehensive, end-to-end integrated approach to drug development for central nervous system (CNS) therapeutics can take you seamlessly from lead candidate selection to market.

With detailed case studies, study considerations, and more, this issue covers:

  • preclinical safety and toxicity testing,
  • formulation and manufacturing,
  • early-phase clinical trials, and
  • bioanalysis.
Read the issue now